Mazdutide is glucagon/GLP-1 dual receptor agonist (Innovent in China; Eli Lilly elsewhere). Mazdutide is a weekly injection acting on glucagon and GLP-1 receptors. Innovent markets it in China, where it was approved in 2025; it is not approved in the US.
Education only. Not medical advice. No dosing information.
Status (verified Oct 29, 2026): Approved in China (NMPA: obesity Jun 2025, type 2 diabetes Sep 2025); not FDA approved. Source: China NMPA approval for weight management (Innovent filing)
Evidence tier: Phase 3 trials; approved outside US
Get alerts on legal status changes ->
What it is
Mazdutide is a weekly injection acting on glucagon and GLP-1 receptors. Innovent markets it in China, where it was approved in 2025; it is not approved in the US.
How it works
GLP-1 activity lowers appetite and glucagon activity may increase energy use and lower liver fat.
What it's researched for
Obesity and type 2 diabetes.
Where it shows up on Peptide Horizon
Regulatory and research timeline
- 2025-06: GLORY-1 Phase 3 published in NEJM (source)
- 2025-06: China NMPA approval for weight management (Innovent filing) (source)
Key trials and studies
FAQ
Is mazdutide FDA approved?
No. It is approved in China but not by the FDA.
Mazdutide vs survodutide?
Both are glucagon/GLP-1 dual agonists from different companies.
Who makes mazdutide?
Innovent in China, licensed from Eli Lilly.
Related peptides
- survodutide FDA status and research
- retatrutide FDA status and research
- tirzepatide FDA status and research
Get alerts on legal status changes
Free email alerts when the FDA, HHS or another regulator changes the status of Mazdutide or other peptides. Get alerts ->
Sources
- https://pubmed.ncbi.nlm.nih.gov/40421736
- https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0627/2025062700759.pdf
Editorial review - Last reviewed Oct 29, 2026